Recursion Pharmaceuticals, Inc. (RXRX) Shareholders’ equity 2019–2025
Recursion Pharmaceuticals, Inc. (RXRX) shareholders’ equity at each fiscal year-end, per SEC filings.
$1.1BFY2025 · since FY2019: -$124.3M → $1.1B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $1.1B | +9.3% |
| FY2024 | $1.0B | +123.3% |
| FY2023 | $463.4M | -4.6% |
| FY2022 | $485.8M | -10.5% |
| FY2021 | $542.9M | +363.2% |
| FY2020 | -$206.3M | -66.0% |
| FY2019 | -$124.3M | — |
Source: SEC XBRL filings · For reference only · Not investment advice